Skip to main content

Table 2 Clinical features and percentage of CD62L positive CD62LCD4+ T cells in 6 patients who discontinued the NTZ treatment

From: Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells

   During NTZ infusion After NTZ withdrawal
  JCV index Number of infusion CD62LCD4 (%) Number of months CD62LCD4 (%) MRI Relapse
Pt #1 3.498 40 5.65 5 49.07 Neg None
Pt #2 2.488 16 16.34 3 56.48 Neg None
Pt #3 2.696 20 35.44 4 32.21 Pos 1
Pt #4 2.034 71 44.50 3 42.32 Neg None
Pt #5 1.366 66 15.83 4 56.59 Neg None
Pt #6 2.304 32 41.18 3 27.78 Neg None
  1. Neg unvaried number of lesions compared to previous MRI